<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Maternal &amp; Fetal Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1C19F7AF-5A4B-4B2D-A649-3A45425290A4"><gtr:id>1C19F7AF-5A4B-4B2D-A649-3A45425290A4</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Jacobs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401619"><gtr:id>45614D29-9807-4FEC-8A9C-585961515350</gtr:id><gtr:title>Proteomic analysis of the human serum proteome ( UCL/Royal Holloway component)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401619</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This proposal is designed to establish the potential of the human serum proteome for screening and diagnosis in large populations using existing cutting-edge technologies for high-throughput protein analysis and biomarker discovery. Recent publications have suggested that serum proteomic analysis has great potential for diagnosis and early detection of human disease. However, these studies have been criticised because of the absence of a systematic approach carefully assessing the numerous variables in sample handling, instrument performance and data analysis as well as concerns about sample selection. We will systematically assess several technologies (including SELDI, nanoESI/Advion and microfluidic sample preparation/Gyrolab) for analysis of the serum proteome utilising powerful data management/bioinformatics approaches and the unique MRC funded UKCTOCS serum bank prospectively collected from 200,000 postmenopausal women. Phase I of the project will assess the impact of sample preparation, physiological variation and instrument variation on the results of proteomic analysis and identify the optimal technology for further studies. Phase II will apply the optimal proteomic technology to case control sample sets in the UKCTOCS serum bank to establish the diagnostic and screening potential of the technology for cancers (eg. breast, colon, ovary) and other common disorders (eg. MI, DVT). In Phase III the biomarkers responsible for the disease-specific patterns documented in Phase II will be identified so that antibodies can be produced and robust clinical screening tools developed. The proposal, which will also link into our ongoing genomic studies of disease risk susceptibility and prognostic prediction in Phase IV, brings together groups with established expertise in proteomics, bioinformatics, data management, population screening and molecular genetics as well as building on the value of the UKCTOCS serum bank. Most of the mass spectrometry/proteomics equipment required for the study is available within our group. The funding required (#~1.3m over 3 years) is therefore primarily for consumables and staff with a component for additional equipment.</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>455572</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biological Sciences Reading</gtr:department><gtr:description>Proteomic profiling of human sera for biomarker discovery</gtr:description><gtr:id>E91E4BE7-A918-423C-BA5F-5879B66FA713</gtr:id><gtr:impact>Five peer-reviewed publications. Award of CR-UK Programme Grant in risk prediction and ealry detection of ovarian cancer. The collaboration on biomarker discovery continues.</gtr:impact><gtr:outcomeId>B5476D17441-1</gtr:outcomeId><gtr:partnerContribution>The development and application of different proteomic technologies for serum biomarker discovery and data analysis</gtr:partnerContribution><gtr:piContribution>The development of technologies for serum profiling and the provision of clinical, control and pre-diagnosis serum samples from cases of ovarian, breast cancer and heart disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Liver and Digestive Health</gtr:department><gtr:description>Discovery of biomarkers of biliary tract and pancreatic cancer</gtr:description><gtr:id>5111C0EC-AE9E-4DB9-B80F-39B7A7EB2494</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers and one publications accepted and another submitted.</gtr:impact><gtr:outcomeId>F22F9E6B2E2-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryAccess to case control samples of benign pancreatic disease and pancreatic cancer for biomarker discovery</gtr:partnerContribution><gtr:piContribution>Proteomic profiling of clinical and control samples of biliary tract cancer and training of a PhD student. Proteomic profiling of pre-diagnosis and matched healthy control serum samples and case controls in a pancreatic cancer biomarker discovery and validation project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medicine and Surgery</gtr:department><gtr:description>Discovery of biomarkers of biliary tract and pancreatic cancer</gtr:description><gtr:id>554098D6-908C-4DC4-9C1D-DB53370E5F20</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers and one publications accepted and another submitted.</gtr:impact><gtr:outcomeId>F22F9E6B2E2-2</gtr:outcomeId><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryAccess to case control samples of benign pancreatic disease and pancreatic cancer for biomarker discovery</gtr:partnerContribution><gtr:piContribution>Proteomic profiling of clinical and control samples of biliary tract cancer and training of a PhD student. Proteomic profiling of pre-diagnosis and matched healthy control serum samples and case controls in a pancreatic cancer biomarker discovery and validation project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visits by potential charity donors</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>476312C1-C56D-4E59-8153-3D3B1FD4CC11</gtr:id><gtr:impact>Several goups of charity donors and fundraisers vistied the laboratory to learn about our work and how the charity funding is used.

Futher visits by similar groups have been initiated</gtr:impact><gtr:outcomeId>M6TaFsk9icz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to charity board of trustees</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E5E6FB50-C1EE-48A4-B032-E4FA69EC9CA4</gtr:id><gtr:impact>Presentations were given to the Board Of Trustees of the Eve Appeal Gynaecological to provide an update and progress on research into biomarkers of ovarian cancer

Ongoing core funding was obtained to support the activities of the research</gtr:impact><gtr:outcomeId>DC0AE0AD64B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1620000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRC Programme Grant -CRUK component</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C1005/A12677</gtr:fundingRef><gtr:id>83F08F18-84BE-4B10-9092-B16555DF1CA6</gtr:id><gtr:outcomeId>RGDmQzJufeK0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1641890</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRC Programme grant - EVE Appeal component</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>The Eve Appeal</gtr:fundingOrg><gtr:id>45BDDD2D-9FF2-4BCF-8270-B29C1109AA5F</gtr:id><gtr:outcomeId>RGDmQzJufeK1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145154</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK TRICC Project Grant</gtr:description><gtr:end>2010-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>4322094E-6212-4C93-9263-BB11538470C3</gtr:id><gtr:outcomeId>T7694Hu6Qi40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK BIDD Project Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>249B130F-D4A3-486E-A23B-F337397944BD</gtr:id><gtr:outcomeId>nUs7PZJAZSc0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Computer algorithms were developed for the processing and statistical analysis of high-throughput MALDI-TOF data and for the identification of MS peaks for ealry detection of cancer</gtr:description><gtr:id>8EBE4D67-8A57-4C39-8889-CB12FD45271D</gtr:id><gtr:impact>The developed algorithms have been used to analyse multiple proteomic datasets</gtr:impact><gtr:outcomeId>70DC816A719</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Algorithms for statistical analysis of MALDI-TOF MS data</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A platform incorporating robotic extraction of peptides from serum on magnetic beads and sample spotting linked to automated MALDI-TOF MS data acquisition was developed for high-throughput profiling of low-mass polypeptides in the serum of clinical sample sets</gtr:description><gtr:id>7FF0C8FD-B416-4234-B66C-28D99B135ADB</gtr:id><gtr:impact>The platform has been applied on mutliple biomarker discovery projects using serum from case control collections and pre-diagnosis samples from UKCTOCS</gtr:impact><gtr:outcomeId>11D5901D737</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A reproducible platform for serum peptide profiling</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The identities of low-molecular weight serum peptides found using our profiling platform has been determined and a database of these assembled for reference in future profiling studies</gtr:description><gtr:id>5D5F7569-C994-4B4B-9BE8-27C41EC5F94E</gtr:id><gtr:impact>Publication of the data and use in other biomarker discovery projects</gtr:impact><gtr:outcomeId>QiekSU3epjY</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A database of serum peptide identifications</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>621C99B9-D91E-4C49-B39E-22967B36F0E0</gtr:id><gtr:title>Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn><gtr:outcomeId>F1w4MyDTSM3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27B682AA-702D-4D4F-B25C-0BDD29EEB3F3</gtr:id><gtr:title>Conformal predictors in early diagnostics of ovarian and breast cancers</gtr:title><gtr:parentPublicationTitle>Progress in Artificial Intelligence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84ebf8ae840f2fb8813384582b293eae"><gtr:id>84ebf8ae840f2fb8813384582b293eae</gtr:id><gtr:otherNames>Devetyarov D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>eBRckZE1pet</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D427D87C-7F5C-4D2D-9A98-10CB6477A367</gtr:id><gtr:title>Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>fGMa2KGC11w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A07B65D-AF94-44AC-90DD-03069ABBE5BA</gtr:id><gtr:title>Preanalytic influence of sample handling on SELDI-TOF serum protein profiles.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn><gtr:outcomeId>8CD54537CAB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FCF98D9-AC46-48E6-92D3-C0CE669955FE</gtr:id><gtr:title>A well-characterised peak identification list of MALDI MS profile peaks for human blood serum.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>V1CicEjaJH3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DA17088-321F-4CF8-84BC-3A1126E7B95A</gtr:id><gtr:title>Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>6BA3616AB93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2C8196C-5744-4FDE-9B6C-7DB8B793CEAE</gtr:id><gtr:title>Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer</gtr:title><gtr:parentPublicationTitle>The Computer Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbed0507bb5763c3f73c6aa548d50a77"><gtr:id>cbed0507bb5763c3f73c6aa548d50a77</gtr:id><gtr:otherNames>Gammerman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>AB3C9C75AC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98B00CAC-52EF-412E-8EF2-23FE90CC7E74</gtr:id><gtr:title>Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.</gtr:title><gtr:parentPublicationTitle>Cancer genomics &amp; proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1109-6535</gtr:issn><gtr:outcomeId>WeyHCr7wuY8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401619</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>